Abstract
The endocannabinoid system comprises amides, esters and ethers of long chain polyunsaturated fatty acids. Narachidonoylethanolamide (anandamide; ANA) and 2-arachidonoylglycerol (2-AG) are endogenous cannabinoids (endocannabinoids) ligands for the cannabinoid family of G-protein-coupled receptors named CB1 and CB2. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and behave as retrograde signaling messengers, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters systems. The two principal enzymes that are responsible for the metabolism of ANA and 2-AG are fatty acid amide hydrolase and monoacylglycerol lipase, respectively. Pharmacological experiments have shown that the administration of endocannabinoids induce cannabimimetic effects, including sleep promotion. This review will focus on some of the current evidence of the pharmacological potential of the endocannabinoid system on sleep modulation.
Keywords: Anandamide, cannabinoids, cannabidiol, rapid eye movement sleep, cannabinoid receptors, VDM-11
Central Nervous System Agents in Medicinal Chemistry
Title: The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation
Volume: 11 Issue: 3
Author(s): Eric Murillo-Rodriguez, Alwin Poot-Ake, Oscar Arias-Carrion, Elda Pacheco-Pantoja, Alfredo de la Fuente-Ortegon and Gloria Arankowsky-Sandoval
Affiliation:
Keywords: Anandamide, cannabinoids, cannabidiol, rapid eye movement sleep, cannabinoid receptors, VDM-11
Abstract: The endocannabinoid system comprises amides, esters and ethers of long chain polyunsaturated fatty acids. Narachidonoylethanolamide (anandamide; ANA) and 2-arachidonoylglycerol (2-AG) are endogenous cannabinoids (endocannabinoids) ligands for the cannabinoid family of G-protein-coupled receptors named CB1 and CB2. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and behave as retrograde signaling messengers, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters systems. The two principal enzymes that are responsible for the metabolism of ANA and 2-AG are fatty acid amide hydrolase and monoacylglycerol lipase, respectively. Pharmacological experiments have shown that the administration of endocannabinoids induce cannabimimetic effects, including sleep promotion. This review will focus on some of the current evidence of the pharmacological potential of the endocannabinoid system on sleep modulation.
Export Options
About this article
Cite this article as:
Murillo-Rodriguez Eric, Poot-Ake Alwin, Arias-Carrion Oscar, Pacheco-Pantoja Elda, de la Fuente-Ortegon Alfredo and Arankowsky-Sandoval Gloria, The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (3) . https://dx.doi.org/10.2174/187152411798047780
DOI https://dx.doi.org/10.2174/187152411798047780 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HSP60 as a Drug Target
Current Pharmaceutical Design MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential
Current Medicinal Chemistry Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB
Anti-Cancer Agents in Medicinal Chemistry Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Current Concepts and Future Directions in Radioimmunotherapy
Current Drug Discovery Technologies Identification of Novel Key Targets and Candidate Drugs in Oral Squamous Cell Carcinoma
Current Bioinformatics Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry miRNA Regulation of Glutathione Homeostasis in Cancer Initiation, Progression and Therapy Resistance
MicroRNA Top-Down Versus Bottom-Up Nanoengineering Routes to Design Advanced Oropharmacological Products
Current Pharmaceutical Design The Antimalarial Drug Pyronaridine Inhibits Topoisomerase II in Breast Cancer Cells and Hinders Tumor Progression In Vivo
Clinical Cancer Drugs